I felt like the worst mother in the world that I didn’t think about RSV sooner,” Schweet reflects. “Travel puts new parents ...

RSV is a virus that can make people sick, especially older adults and babies. But even though RSV can be serious, people aren't as worried about it anymore. RSV is common but can be dangerous ...

Dr. Paul Roumeliotis knows first-hand how dangerous RSV (respiratory syncytial virus) can be for tiny babies. The pediatrician and medical officer of health at the Eastern Ontario Health Unit has ...

For some folks, the fall to-do list should now include an important third jab—a respiratory syncytial virus (RSV) vaccine. (The FDA approved the first one in 2023.) While flu and COVID cases ...

RSV vaccines hold the potential to reduce the thousands of hospitalizations and deaths associated with the virus in the US each year. But vaccines are only effective if they get in the arms of the ...

Now that’s the stuff of sleepless nights. For most healthy people, RSV feels like a cold—annoying, but nothing super serious. But babies, especially those under six months old, are especially ...

New images of the virus may hold the key to preventing or slowing RSV infections. RSV is of greatest concern in young children, the elderly and adults. The complex shape of respiratory syncytial ...

RSV is a highly contagious virus affecting the respiratory system, especially dangerous for infants, young children, and pregnant women. It leads to symptoms ranging from mild colds to severe ...

The patents in contention are numbers 3,109,258, 2,222,710 and 3,178,490, all awarded by the European Patent Office and covering recombinant RSV antigens and compositions and methods for making them.

A global real-world study of the vaccine for respiratory syncytial virus (RSV) finds it offers folks aged 60 and over 80% protection against severe illness and/or hospitalization. With U.S ...

2:05 Access to infant RSV protection differs across Canada The World Health Organization on Tuesday recommended maternal vaccination and the use of an antibody therapy to prevent respiratory ...

In the 2023 to 2024 respiratory syncytial virus (RSV) season, more than half of infants were protected by maternal RSV vaccine, nirsevimab, or both, according to research published in the Sep.